Responses
Regular and young investigator award abstracts
Novel single-agent immunotherapies
721 AT1412, a patient-derived CD9 antibody in preclinical development promoting tumor immune infiltration and inducing tumor rejection
Compose a Response to This Article
Other responses
No responses have been published for this article.
